The application of telmisartan in central nervous system disorders
- PMID: 40536710
- DOI: 10.1007/s43440-025-00737-2
The application of telmisartan in central nervous system disorders
Abstract
Telmisartan, a well-established antihypertensive drug, has shown promising therapeutic potential for a variety of central nervous system (CNS) disorders. This review outlines the fundamental characteristics of telmisartan, focusing on its dual pharmacological effects as an angiotensin II type 1 receptor (AT1R) antagonist and a peroxisome proliferator-activated receptor (PPAR) γ activator. These mechanisms underpin its neuroprotective and anti-inflammatory effects, which are essential to its therapeutic benefits in CNS diseases. Telmisartan modulates key cellular components of the CNS, including microglia, astrocytes, oligodendrocytes, vascular endothelial cells, and neurons, thereby offering protection against neuroinflammation, oxidative stress, and neuronal damage. We summarize telmisartan's efficacy in addressing a range of neurological conditions, such as stroke, traumatic brain injury, dementia, Parkinson's disease, demyelinating diseases, psychiatric disorders, and gliomas. By targeting multiple pathways involved in these disorders, telmisartan demonstrates potential as both an adjunctive and standalone therapy. Its ability to attenuate neuroinflammation and promote cellular repair highlights its versatility in CNS disease management. This review underscores the potential of telmisartan as a valuable therapeutic option for CNS disorders, warranting continued exploration to optimize its clinical application.
Keywords: AT1R; Central nervous system; Neuroinflammation; PPARγ; Telmisartan.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Similar articles
-
Enhancing the diagnostic potential of electroretinography in Parkinson's disease: A review of protocol and cohort criteria.J Parkinsons Dis. 2025 Jun;15(4):694-709. doi: 10.1177/1877718X251331863. Epub 2025 Apr 29. J Parkinsons Dis. 2025. PMID: 40530583 Review.
-
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x. Respir Res. 2024. PMID: 39709425 Free PMC article. Review.
-
Temperature sensitivity of spreading depolarization in the CNS of Drosophila melanogaster.Am J Physiol Regul Integr Comp Physiol. 2025 Jul 1;329(1):R134-R149. doi: 10.1152/ajpregu.00040.2025. Epub 2025 May 20. Am J Physiol Regul Integr Comp Physiol. 2025. PMID: 40392029
-
Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system.J Neurovirol. 2014 Feb;20(1):39-53. doi: 10.1007/s13365-013-0227-1. Epub 2014 Jan 14. J Neurovirol. 2014. PMID: 24420448 Free PMC article.
-
Dingzhen pills inhibit neuronal ferroptosis and neuroinflammation by inhibiting the cGAS-STING pathway for Parkinson's disease mice.Chin Med. 2025 Jun 16;20(1):87. doi: 10.1186/s13020-025-01135-9. Chin Med. 2025. PMID: 40524254 Free PMC article.
References
-
- Hattori N, Yamada A, Nakatsuji S, Matsuda T, Nishiyama N, Shimatsu A.Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes. J Mol Endocrinol. 2022;69(1):259–68. - PubMed
Publication types
LinkOut - more resources
Full Text Sources